Novo Nordisk
· NVO
Rev. 1Y%
31.26%
RPS 3Y CAGR
23.97%
RPS 10Y CAGR
5.21%
EPS 1Y%
52.28%
EPS 3Y CAGR
27.40%
EPS 10Y CAGR
7.10%
Gross Margin
84.53%
Op. Inc. Margin
43.26%
Profit Margin
34.84%
ROE
87.50%
ROA
24.34%
ROCE
61.51%
$0
525.84 B
40.60
47.69
13.90
54.32
Competitive Advantages
Strong Brand and Reputation: Renowned for its innovative and high-quality diabetes and rare disease treatments.
Leading Market Position in Diabetes: Dominates the global insulin market with a wide range of products and services.
Risks
Competition and Price Pressure: Intense competition from other pharmaceutical companies developing and marketing similar diabetes and obesity treatments.
Clinical Trial Results: Failure or unexpected outcomes in clinical trials for new or existing drugs, impacting revenue and reputation.